Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study

• Published in: Journal of clinical medicine Vol. 11; no. 14; p. 4178
• Main Authors: D'Angelo, Salvatore, Tirri, Enrico, Giardino, Angela Maria, Mattucci-Cerinic, Marco, Dagna, Lorenzo, Santo, Leonardo, Ciccia, Francesco, Frediani, Bruno, Govoni, Marcello, Bobbio Pallavicini, Francesca, Grembiale, Rosa Daniela, Delle Sedie, Andrea, Mulè, Rita, Cantatore, Francesco Paolo, Foti, Rosario, Gremese, Elisa, Conigliaro, Paola, Salaffi, Fausto, Viapiana, Ombretta, Cauli, Alberto, Giacomelli, Roberto, Arcarese, Luisa, Guggino, Giuliana, Russo, Romualdo, Puenpatom, Amy, Capocotta, Domenico, Nacci, Francesca, Anelli, Maria Grazia, Picerno, Valentina, Binetti, Corrado, Iannone, Florenzo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19.07.2022; MDPI
• Subjects: Clinical medicine; Confidence intervals; COVID-19; Disease; Drugs; Monoclonal antibodies; Observational studies; Patients; Performance evaluation; Psoriatic arthritis; Quality of life; Rheumatoid arthritis; Rheumatology; Sample size; Software; TNF inhibitors; Tumor necrosis factor-TNF; United States > US; Italy; anti-TNF inhibitor; psoriatic arthritis; axial spondyloarthritis; rheumatoid arthritis; golimumab; biologic
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11144178

In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were also assessed. A total of 194 patients aged 53.2 ± 12 years started GLM as a second anti-TNF drug: 39 (20.1%) with RA, 91 (46.9%) with PsA and 64 (32.9%) with axSpA. After 6 months of GLM treatment, 68% of RA patients achieved low disease activity (LDA; DAS28-CRP ≤ 3.2), 31.9% of PsA patients achieved minimal disease activity and 32.5% of axSpA patients achieved LDA (ASDAS-CRP < 2.1). Good/moderate EULAR response was achieved in 61.9% and 73.8% of patients with RA and PsA, respectively, and 16% of axSpA patients achieved a 50% improvement in BASDAI. Across all indications, improvements in disease activity measures and EQ-5D-5L domains were observed over 6 months. The main reasons for GLM interruption were lack/loss of efficacy (7.2%) or adverse events (2%). This study confirms the effectiveness of GLM as a second-line anti-TNF for the treatment of RA, PsA and axSpA in a real-world setting in Italy.